Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Inventory (2018 - 2025)

Akebia Therapeutics (AKBA) has disclosed Inventory for 8 consecutive years, with $15.6 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 3.9% to $15.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.6 million through Dec 2025, down 3.9% year-over-year, with the annual reading at $15.6 million for FY2025, 3.9% down from the prior year.
  • Inventory for Q4 2025 was $15.6 million at Akebia Therapeutics, down from $18.6 million in the prior quarter.
  • The five-year high for Inventory was $45.2 million in Q3 2022, with the low at $15.6 million in Q4 2025.
  • Average Inventory over 5 years is $26.7 million, with a median of $21.2 million recorded in 2022.
  • The sharpest move saw Inventory tumbled 63.77% in 2021, then soared 34.3% in 2022.
  • Over 5 years, Inventory stood at $36.6 million in 2021, then crashed by 41.12% to $21.6 million in 2022, then dropped by 27.25% to $15.7 million in 2023, then rose by 3.52% to $16.2 million in 2024, then decreased by 3.9% to $15.6 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $15.6 million, $18.6 million, and $16.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.